Pediatric blood & cancer
-
Pediatric blood & cancer · Apr 2020
Clinical TrialRuxolitinib salvage therapy is effective for steroid-refractory graft-versus-host disease in children: A single-center experience.
Despite the increasing performance of allogeneic hematopoietic cell transplantation over the last decades, graft-versus-host disease (GVHD) remains the main cause of morbidity and mortality. The efficacy of ruxolitinib against GVHD has been demonstrated in adult studies; however, very few studies have been conducted in children. ⋯ Steroid-refractory acute and chronic pediatric GVHD patients treated with ruxolitinib had a high overall response rate, with the additional benefit of steroid sparing.
-
Pediatric blood & cancer · Apr 2020
Multicenter StudyProtein biomarkers for incident deep venous thrombosis in critically ill adolescents: An exploratory study.
There are no tests to identify critically ill children at high risk of deep venous thrombosis (DVT). In this exploratory study, we aimed to identify proteins that are associated with incident DVT in critically ill adolescents. ⋯ We identified candidate protein biomarkers for incident DVT. We plan to validate our findings in adequately powered studies.
-
Pediatric blood & cancer · Apr 2020
Vitamin D status in children with leukemia, its predictors, and association with outcome.
Children and adolescents with leukemia are potentially at high risk of vitamin D inadequacy, which may have clinical relevance for skeletal morbidity, infections, and cancer outcome. This study aimed to evaluate vitamin D status at the time of diagnosis to investigate its predictors and association with overall survival in children with leukemia. ⋯ It remains unclear whether vitamin D supplementation in pediatric leukemia patients will improve outcome.